{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:27:17Z","timestamp":1778884037869,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006704","name":"University of Ostrava","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jns.2024.122910","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:22:39Z","timestamp":1706790159000},"page":"122910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study"],"prefix":"10.1016","volume":"458","author":[{"given":"Zuzana Krska","family":"Kusnirikova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Kacirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Pesakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Hradilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Brozmanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jns.2024.122910_bb0005","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurol. Clin."},{"issue":"11","key":"10.1016\/j.jns.2024.122910_bb0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2024.122910_bb0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2024.122910_bb0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.jns.2024.122910_bb0025","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jns.2024.122910_bb0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/17425255.2013.800483","article-title":"Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis","volume":"9","author":"Wiese","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.jns.2024.122910_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","article-title":"Immune mechanisms of new therapeutic strategies in MS: teriflunomide","volume":"142","author":"Claussen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2024.122910_bb0040","author":"Sanofi-Aventis"},{"issue":"2","key":"10.1016\/j.jns.2024.122910_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40263-023-00985-x","article-title":"Teriflunomide concentrations in cerebrospinal fluid and plasma in patients with multiple sclerosis: a pharmacokinetic study","volume":"37","author":"Lycke","year":"2023","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jns.2024.122910_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide\u2019s use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener Dis Manag."},{"issue":"7","key":"10.1016\/j.jns.2024.122910_bb0055","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/ard.2007.086264","article-title":"Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance","volume":"68","author":"Kis","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"224","key":"10.1016\/j.jns.2024.122910_bb0060","article-title":"Liquid chromatography-tandem mass spectrometry method for determination of total and free teriflunomide concentration in serum of patients with multiple sclerosis","volume":"5","author":"Pesakova","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jns.2024.122910_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40261-019-00786-5","article-title":"Safety, pharmacokinetics, and pharmacogenetics of single-dose Teriflunomide sodium and Leflunomide in healthy Chinese subjects","volume":"39","author":"Yao","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jns.2024.122910_bb0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/jpm11050335","article-title":"Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis","volume":"11","author":"Zarzuelo Romero","year":"2021","journal-title":"J. Pers. Med."},{"issue":"21","key":"10.1016\/j.jns.2024.122910_bb0080","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jns.2024.122910_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.116.071985","article-title":"Intracellular CD3+ T lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration","volume":"45","author":"Hopkins","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jns.2024.122910_bb0090","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41598-022-05644-7","article-title":"Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels","volume":"12","author":"Fajardo-Robledo","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jns.2024.122910_bb0095","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr.24236","article-title":"Precision medicine with leflunomide: consideration of the DHODH haplotype and plasma teriflunomide concentration and modification of outcomes in patients with rheumatoid arthritis","volume":"73","author":"Wiese","year":"2021","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jns.2024.122910_bb0100","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/ard.2008.099093","article-title":"Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis","volume":"68","author":"Grabar","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2024.122910_bb0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.2004.025205","article-title":"Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis","volume":"64","author":"van Roon","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2024.122910_bb0110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.2005.02415.x","article-title":"Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis","volume":"60","author":"Chan","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2024.122910_bb0115","series-title":"COST B1 Medicine: European Cooperation in the Field of Scientific and Technical Research","first-page":"238","article-title":"The population approach: Measuring and managing variability in response, concentration and dose","author":"Weber","year":"1997"},{"issue":"1","key":"10.1016\/j.jns.2024.122910_bb0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40744-016-0025-3","article-title":"Chronic diarrhea associated with high teriflunomide blood concentration","volume":"3","author":"Duquette","year":"2016","journal-title":"Rheumatol. Ther."},{"issue":"13","key":"10.1016\/j.jns.2024.122910_bb0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2024.122910_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Kappos L; OPERA I and OPERA II clinical investigators. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.122910_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Wolinsky JS; ORATORIO clinical investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2024.122910_bb0140","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of Higher Ocrelizumab Exposure with Reduced Disability Progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:05Z","timestamp":1758384305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"alternative-id":["S0022510X24000455"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122910","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122910"}}